T1	intervention 37 59	HER2/neu (E75) vaccine
T2	location 130 133	U.S
T3	eligibility 394 458	node-positive (NP) and node-negative (NN) breast cancer patients
T4	outcome-Measure 717 744	Local and systemic toxicity
T5	outcome-Measure 760 781	Immunologic responses
T6	outcome-Measure 871 891	Clinical recurrences
T7	No-of-participants 909 935	One hundred and eighty-six
T8	intervention-participants 1073 1076	101
T9	control-participants 1103 1105	85
T10	control 1138 1146	controls
T11	outcome 1277 1292	recurrence rate
T12	intervention-value 1296 1300	5.6%
T13	control-value 1338 1343	14.2%
T14	outcome 1457 1481	difference in recurrence
T15	intervention-value 1531 1535	8.3%
T16	control-value 1543 1548	14.8%
